Compare SLVM & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLVM | TRAX |
|---|---|---|
| Founded | 1898 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | 2026 |
| Metric | SLVM | TRAX |
|---|---|---|
| Price | $32.28 | $35.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $48.00 | ★ $72.50 |
| AVG Volume (30 Days) | 336.7K | ★ 1.0M |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | ★ 5.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.40 | $15.69 |
| 52 Week High | $56.80 | $49.91 |
| Indicator | SLVM | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 48.71 |
| Support Level | N/A | $30.11 |
| Resistance Level | $40.13 | $48.94 |
| Average True Range (ATR) | 1.33 | 2.84 |
| MACD | -0.07 | 0.26 |
| Stochastic Oscillator | 35.25 | 46.87 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.